肠易激综合征的治疗现状及研究进展

被引：26

作者：

于洪波

李爱萍

戴林

机构：

[1] 解放军第医院消化内科

来源：

胃肠病学和肝病学杂志 | 2014年 / 23卷 / 06期

关键词：

肠易激综合征; 药物; 治疗;

D O I：

暂无

中图分类号：

R574 [肠疾病];

学科分类号：

100201 [内科学];

摘要：

肠易激综合征(irritable bowel syndrome,IBS)是一种发病率最高的功能性疾病,严重影响着患者的生活质量,且"有病乱投医、滥用药"现象严重,耗费了大量的医疗资源。目前,已应用于临床的一些药物的实际疗效尚有一定争议,本文对IBS不同亚型的治疗现状和进展作一综述。

引用

页码：609 / 617

页数：9

共 44 条

[1]

针刺与西药治疗肠易激综合征疗效对照观察.[J].石志敏;朱叶珊;王清贤;雷淼娜;.中国针灸.2011, 07

[2]

Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis.[J].Elizabeth J. Videlock;Vivian Cheng;Filippo Cremonini.Clinical Gastroenterology and Hepatology.2013,

[3]

Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome [J].

El-Salhy, Magdy ;

Gundersen, Doris ;

Hatlebakk, Jan Gunnar ;

Hausken, Trygve .

MOLECULAR MEDICINE REPORTS, 2013, 7 (04) :1081-1085

[4]

Tu2079 Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life..[J].Lena Böhn;Stine Störsrud;Hans Törnblom;Ulf J. Bengtsson;Magnus Simren.Gastroenterology.2013, 5S1

[5]

The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults ≤50 years of age [J].

Krogsgaard, Laura Rindom ;

Engsbro, Anne Line ;

Bytzer, Peter .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (05) :523-529

[6]

Atypical antipsychotics as a possible treatment option for irritable bowel syndrome [J].

Pae, Chi-Un ;

Lee, Soo-Jung ;

Han, Changsu ;

Patkar, Ashwin A. ;

Masand, Prakash S. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) :565-572

[7]

The use of psychotropic drugs in irritable bowel syndrome [J].

Dekel, Roy ;

Drossman, Douglas A. ;

Sperber, Ami D. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) :329-339

[8]

Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease [J].

Whelan, Kevin ;

Quigley, Eamonn M. M. .

CURRENT OPINION IN GASTROENTEROLOGY, 2013, 29 (02) :184-189

[9]

Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints.[J].E. M. M. Quigley;J. Tack;W. D. Chey;S. S. Rao;J. Fortea;M. Falques;C. Diaz;S. J. Shiff;M. G. Currie;J. M. Johnston.Aliment Pharmacol Ther.2012, 1

[10]

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.[J].P. Meyrat;E. Safroneeva;A. M. Schoepfer.Aliment Pharmacol Ther.2012, 11pt

← 1 2 3 4 5 →